ストックスクリーナーアプリを入手
3.33
1.83%
0.06
アフターアワーズ：
3.36
0.03
+0.90%
前日終値:
$3.27
開ける：
$3.27
24時間の取引高:
400.25K
Relative Volume:
1.15
時価総額：
$264.26M
収益：
$351.37M
当期純損益:
$-174.01M
株価収益率:
-1.6087
EPS:
-2.07
ネットキャッシュフロー:
$-126.94M
1週間 パフォーマンス:
+2.46%
1か月 パフォーマンス:
+6.05%
6か月 パフォーマンス:
+22.43%
1年 パフォーマンス:
-4.86%
1日の値動き範囲:
$3.25
$3.355
1週間の範囲:
$3.18
$3.355
52週間の値動き範囲:
$2.455
$4.02
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
AVIR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.33 | 259.50M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.20 | 103.89B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.74 | 69.11B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.70 | 58.49B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
869.83 | 52.62B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
191.92 | 40.46B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-13 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-01-06 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-10-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | 開始されました | Evercore ISI | Outperform |
| 2020-11-24 | 開始されました | JP Morgan | Overweight |
| 2020-11-24 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-24 | 開始されました | William Blair | Outperform |
すべてを表示
Atea Pharmaceuticals Inc (AVIR) 最新ニュース
Backtesting results for Atea Pharmaceuticals Inc. trading strategiesJuly 2025 Drop Watch & AI Powered Market Entry Strategies - newser.com
How strong is Atea Pharmaceuticals Inc. stock revenue growthWeekly Profit Report & Smart Money Movement Tracker - newser.com
Key metrics from Atea Pharmaceuticals Inc.’s quarterly dataQuarterly Portfolio Report & Consistent Profit Trading Strategies - newser.com
Atea Pharmaceuticals Inc. stock trend outlook and recovery path2025 Top Decliners & Community Consensus Trade Signals - newser.com
Is Atea Pharmaceuticals Inc. stock reversal real or fakeJuly 2025 Fed Impact & High Accuracy Investment Signals - newser.com
Atea’s hepatitis C drug combination shows promising results in modeling study - Investing.com India
Atea’s hepatitis C drug combination shows promising results in modeling study By Investing.com - Investing.com South Africa
Atea Pharmaceuticals Presents Promising Modeling Data for Bemnifosbuvir and Ruzasvir Combination Therapy in Hepatitis C at The Liver Meeting 2025 - Quiver Quantitative
Atea Pharma (Nasdaq: AVIR) presents 98% SVR12 for BEM/RZR; modeling shows 7–8 week cure - Stock Titan
Is Atea Pharmaceuticals Inc. still worth holding after the dipQuarterly Portfolio Summary & Daily Entry Point Alerts - newser.com
Is a relief rally coming for Atea Pharmaceuticals Inc. holders2025 Big Picture & AI Forecasted Stock Moves - newser.com
Live market analysis of Atea Pharmaceuticals Inc.2025 Market Overview & Fast Moving Market Watchlists - newser.com
Is Atea Pharmaceuticals Inc. stock cheap at current valuation2025 AllTime Highs & Technical Analysis for Trade Confirmation - newser.com
Applying sector rotation models to Atea Pharmaceuticals Inc.July 2025 Sector Moves & AI Driven Stock Movement Reports - newser.com
Atea Pharma (NASDAQ: AVIR) to host Nov. 12 at 4:30 p.m. ET for third-quarter results - Stock Titan
Using economic indicators to assess Atea Pharmaceuticals Inc. potential2025 Key Lessons & Weekly Watchlist for Hot Stocks - newser.com
Atea Pharmaceuticals, Inc. (AVIR) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Atea Pharmaceuticals Advances with Key Phase 1 Study on Bemnifosbuvir/Ruzasvir - MSN
Atea Pharmaceuticals Inc Stock Analysis and ForecastFlag and Pennant Patterns & Outstanding Portfolio Growth - earlytimes.in
Atea Pharmaceuticals, Inc. (AVIR) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
What drives Atea Pharmaceuticals Inc stock priceDividend Reinvestment Plans & Free Fastest Return On Investment - earlytimes.in
Atea Pharmaceuticals Inc (AVIR) 財務データ
収益
当期純利益
現金流量
EPS
Atea Pharmaceuticals Inc (AVIR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
| BERGER FRANKLIN M | Director |
Dec 10 '24 |
Sale |
2.85 |
359,606 |
1,023,475 |
451,897 |
0.05%
1.40%
大文字化:
|
ボリューム (24 時間):